Review Open Access
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Mar 26, 2015; 7(3): 134-143
Published online Mar 26, 2015. doi: 10.4330/wjc.v7.i3.134
Role of Helicobacter pylori infection in pathogenesis of atherosclerosis
Rajesh Vijayvergiya, Ramalingam Vadivelu, Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
Author contributions: Both the authors have contributed equally to this review article; Vijayvergiya R has done literature search, critical review and analysis of the literature and a revision of the manuscript; and Vadivelu R has performed literature search and review, articles extraction, writing of first draft of the manuscript.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Rajesh Vijayvergiya, MD, DM, FSCAI, FISES, FACC, Additional Professor, Department of Cardiology, Advanced Cardiac Centre, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. rajeshvijay999@hotmail.com
Telephone: +91-172-2756518 Fax: +91-172-2744401
Received: June 24, 2014
Peer-review started: June 24, 2014
First decision: June 24, 2014
Revised: October 4, 2014
Accepted: November 27, 2014
Article in press: December 1, 2014
Published online: March 26, 2015
Processing time: 113 Days and 15.3 Hours

Abstract

Though a century old hypothesis, infection as a cause for atherosclerosis is still a debatable issue. Epidemiological and clinical studies had shown a possible association but inhomogeneity in the study population and study methods along with potential confounders have yielded conflicting results. Infection triggers a chronic inflammatory state which along with other mechanisms such as dyslipidemia, hyper-homocysteinemia, hypercoagulability, impaired glucose metabolism and endothelial dysfunction, contribute in pathogenesis of atherosclerosis. Studies have shown a positive relations between Cytotoxic associated gene-A positive strains of Helicobacter pylori and vascular diseases such as coronary artery disease and stroke. Infection mediated genetic modulation is a new emerging theory in this regard. Further large scale studies on infection and atherosclerosis focusing on multiple pathogenetic mechanisms may help in refining our knowledge in this aspect.

Key Words: Atherosclerosis; Coronary artery disease; Helicobacter pylori; Infection; Stroke

Core tip: Though a century old hypothesis, infection as a cause of atherosclerosis is still a debatable issue. Clinical and epidemiological studies had shown a possible association, however in-homogeneity in the study population and methodology has yielded conflicting results. We performed a literature search on MEDLINE electronic database using keywords such as Helicobacter pylori (H. pylori), infection, atherosclerosis, coronary artery disease, myocardial infarction, stroke, cerebro-vascular disease and peripheral arterial disease using MeSH terms, to review this subject. The association between H. pylori and atherosclerosis is not strong and a causal role is not yet established. Large scale studies on infection and atherosclerosis focusing on multiple pathogenetic mechanisms may help in refining our knowledge in this aspect.



INTRODUCTION

Though a century old hypothesis, infection is still debated as a cause of atherosclerosis[1]. Infection triggers a chronic inflammatory state which along with other mechanisms such as dyslipidemia, hyper-homocysteinaemia, hypercoagulability, impaired glucose metabolism and endothelial dysfunction contribute in pathogenesis of atherosclerosis. Studies have shown a positive relations between Cytotoxic associated gene-A (Cag-A) positive Helicobacter pylori (H. pylori) strains with vascular diseases such as coronary artery disease (CAD) and stroke. Infection mediated genetic modulation is a new emerging theory in this regard. Minick and Fabricant’s work on infection and atherosclerosis in animal model had made the ground for revolutionary research in this field[2,3]. Chronic infection triggers T1 Helper cell (Th1) mediated inflammatory reaction, which plays a crucial role in atherosclerosis. Markers of infection and inflammation were also studied as the risk factors for atherosclerosis[4-6]. An association between infection and atherosclerosis was established following detection of infectious agents from arterial vessels, positive immune-histochemistry studies, detection of microbial DNA sequences in atherosclerotic plaques by PCR method, positive serological response with higher titres in infected patients, and a positive correlation of infection with atherosclerotic burden and dyslipidaemia[7-23]. The microbial agents that have been implicated in the etio-pathogenesis of atherosclerosis are presented in Table 1, Figure 1.

Table 1 Microbial agents associated with atherosclerosis.
BacteriaViruses
Chlamydia pneumoniaH simplex virus type 1 and 2
Helicobacter pyloriCytomegalovirus
Helicobacter cinaediEpstein- Barr virus
Hemophilus influenzaMycoplasma pneumonia
Figure 1
Figure 1 Theories of infection related atherosclerosis.

This review has been divided into two parts. Part I elucidates different mechanisms of H. pylori related atherosclerosis and relevant studies. Part II reviews the literature about H. pylori association with atherosclerotic diseases such as CAD, stroke and peripheral arterial disease (PAD).

MECHANISMS OF H. PYLORI RELATED ATHEROSCLEROSIS

Development of CAD in patients without conventional risk factors suggests a possible role of an additional unexplored mechanism. The evolution of atherosclerosis in the background of chronic inflammatory milieu involves multiple pathways (Table 2, Figure 1). Some of these pathways will be discussed in following section.

Table 2 Mechanisms of Helicobacter pylori related atherosclerosis.
Induction of inflammatory response secondary to chronic infectious state
Endothelial damage
Chronic low grade activation of coagulation cascade
Dysregulation of lipid metabolism resulting in increased total cholesterol and triglyceride levels and reduced high density lipoprotein levels
Hyperhomocysteinaemia
H. pylori and endothelial dysfunction

Infection related chronic vascular inflammation can result in endothelial dysfunction. Tousoulis et al[24] first proposed an inflammatory mechanism for endothelial dysfunction. C-reactive protein (CRP) and inflammatory adhesion molecule such as intracellular adhesion molecule-1 (ICAM-1) are elevated in patients with H. pylori infection, suggesting a possible link between infection and endothelial dysfunction[25]. Chronic infection triggers release of inflammatory cytokines such as interleukin (IL)-1, IL-6 and tumor necrosis factor-α (TNF-α), which affects microvascular vasomotor functions, resulting into vasoconstriction and endothelial dysfunction. Coskun et al[26] studied a possible relation between H. pylori infection in children and endothelial dysfunction as a precursor for future atherosclerosis. There was no significant association between H. pylori seropositivity and CRP levels with flow mediated vasodilation. Another evidence is about increase prevalence of slow flow in the major epicardial coronary arteries in patients with H. pylori infection[27]. The possible mechanism of slow flow was endothelial dysfunction secondary to raised homocysteine levels. H. pylori infection causes malabsorption of vitamin B12 and folic acid and thus increases serum homocysteine levels. Evrengul et al[27] reported a mean TIMI frame count of coronary flow as 46.3 ± 8.7 and 24.3 ± 2.9 in patients with and without H. pylori infection, respectively. An association between H. pylori infection and functional vascular disorders such as cardiac syndrome-X, migraine and primary Reynaud phenomenon provides evidence about its role in endothelial dysfunction and atherosclerosis[28-32].

Chronic inflammation

Presence of chronic, persistent inflammation provides a vital clue for infectious theory of CAD. Chronic H. pylori infection induces a pro-inflammatory state, resulting into an increase in cytokines levels such as TNF-α, Interleukins (IL-1, IL-6, IL-8), gamma interferon, coagulant factors - fibrinogen, thrombin and soluble adhesion molecules such as intercellular adhesion molecule (ICAM-1), vascular cell adhesion molecule (VCAM-1)[33-35]. Eradication of H. pylori infection by use of antibiotics leads to reduction in cytokines levels[34,36]. These evidences suggest that H. pylori induced inflammatory cascade plays an active role in atherosclerosis. Activated T lymphocytes and macrophages following cytokines release induce proliferation of smooth muscle cells and extracellular matrix, which plays a crucial role in pathogenesis of atherosclerosis. It also stimulates metalloproteinases production, which causes rupture of atheroma cap and leads to acute coronary syndromes. However, a large population based study failed to support the association between H. pylori and increased inflammatory cytokines[37].

Recent research has unveiled novel molecular mechanisms of H. pylori mediated inflammation[38-41]. H. pylori infection exerts an immune-inflammatory reaction by activating cyclooxygenase enzyme-2 (COX-2), which causes increase production of prostaglandin (PGE2) and nitric oxide (NO). H. pylori cell wall lipopolysaccharide (LPS) triggers toll-like receptor-4, which activates various secondary mediators such as mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase, c-Jun N-terminal kinase (JNK) and p38 kinase resulting in enhanced stimulation of NOS and COX-2 gene expression[38,39]. LPS-induced activation of MAPK cascade is also associated with epidermal growth factor receptor (EGFR) transactivation which is a key protein regulating cellular proliferation, differentiation, migration and modulation of apoptosis[41]. Gherlin, a peptide hormone activates NO synthase, thereby inhibiting H. pylori LPS induced activation of COX-2 and other inflammatory pathways[40].

H. pylori and hyper-homocysteinaemia

H. pylori causes atrophic gastritis, which is associated with malabsorption of vitamin B12 and folic acid. Deficiency of these vitamins causes hyper-homocysteinaemia due to interruption of re-methylation pathway[42-45]. Hence, it may have a role in the pathogenesis of premature atherosclerosis[45]. In a study by Kutluana et al[45], carotid intima media thickness was found to be higher in patients with H. pylori related atrophic gastritis. In this study, H. pylori positive patients had significantly higher homocysteine levels compared to controls (14.17 ± 9.24 μmol/L vs 9.81 ± 3.42 μmol/L, P = 0.01). Senmaru et al[46] reported a higher prevalence of CAD in atrophic gastritis (5.8% vs 2.8%). Torisu et al[47] had shown an association between increased pulse wave velocity, a preclinical marker of atherosclerosis with atrophic gastritis. Apart from hyper-homocysteinaemia, other mechanisms are reduced ghrelin levels and induction of chronic pro-inflammatory cascade resulting into endothelial damage[46,47]. However, Bloemenkamp et al[48] did not support the hypothesis about H. pylori infection induced hyper-homocysteinemia and atherosclerosis.

H. pylori and dyslipidemia

H. pylori infection is associated with lower HDL cholesterol (HDL-C) and higher total cholesterol (TC), LDL cholesterol (LDL-C) and triglyceride levels. Higher apolipoprotein-B and lower apolipoprotein-A (apo-A) levels were also reported[11]. Murray et al[49] demonstrated that women with H. pylori infection had lower HDL-C (P = 0.006). Another study had also shown significantly lower HDL-C levels in infected patients[11]. Niemelä et al[50] and Laurila et al[22] reported an increase triglyceride levels in H. pylori positive patients. These alterations in lipid homeostasis proved to be significant even after adjusting co-variables such as socioeconomic class, body weight, age and diabetic status[22,51]. de Luis et al[52] showed that eradication of H. pylori decreases apo-A and increases HDL-C. Other studies had also shown reduction in TC, LDL-C levels and increase in HDL-C, apo-AI and apo-AII levels following H. pylori eradication[53-55]. However, this association was not supported by few other authors[56-59].

H. pylori, impaired glucose metabolism and metabolic syndrome

Gillum et al[60] reported a significant association of H. pylori seropositivity with CAD in diabetic males. de Luis et al[51] showed that CAD and cerebrovascular diseases were significantly more seen in H. pylori infected diabetic patients. Yoshikawa et al[61] suggested that H. pylori seropositivity increases brachial-ankle pulse wave velocity, a marker of atherosclerosis, in patients with impaired glucose metabolism. Aydemir et al[62] reported that H. pylori positive subjects had higher homeostatic model assessment-insulin resistance (HOMA-IR) levels (2.56 ± 1.54 vs 1.73 ± 1.1, P < 0.05), a surrogate of insulin resistance, as compared to H. pylori negative controls. Aslan et al[63] had shown that paraoxanase, a marker of oxidative stress is well correlated with HOMA-IR levels and is significantly elevated in H. pylori positive patients. Regarding role of H. pylori eradication therapy in improvement of glucose tolerance, Gen et al[64] reported that HOMA-IR level significantly reduced after successful therapy, whereas Park et al[65] did not show any significant reduction. Polyzos et al[66] in his systematic review concluded that available evidences indicate a potential association between H. pylori infection and insulin resistance. Gunji et al[67] reported that H. pylori infection was significantly and independently associated with metabolic syndrome. A recent study by Ando et al[68] revealed that eradication of H. pylori increases circulating adiponectin levels and might be helpful in prevention of metabolic syndrome. Naja et al[69] suggested no association between H. pylori infection and metabolic syndrome or impaired glucose tolerance.

H. pylori, hypertension and arterial stiffness

Migneco et al[70] demonstrated a significant reduction in blood pressure after eradication of H. pylori in hypertensive subjects. The possible association of H. pylori with arterial stiffness was initially reported by Adachi and Yoshikawa. Adachi et al[71] reported that carotid pulse wave velocity was higher in seropositive subjects. Yoshikawa et al[61] similarly reported a higher brachial-ankle pulse wave velocity in seropositive patients with impaired glucose metabolism. The possible association of H. pylori and arterial stiffness tends to be more in younger subjects, whereas in the elderly arterial stiffness is more often due to aging[72]. Honda et al[73] demonstrated that H. pylori infection did not affect the age related progression of arteriosclerosis over a 4 years follow-up period.

EVIDENCE OF ASSOCIATION BETWEEN H. PYLORI AND ATHEROSCLEROSIS
H. pylori and CAD

Demonstration of an association between H. pylori and CAD is always challenging. Both conditions are more prevalent in the population, increases with age and are related to socioeconomic status. The following section reviews the evidence of H. pylori association with CAD.

Numerous studies have shown that CAD patients have a higher prevalence of H. pylori infection[74-77]. Vijayvergiya et al[77] demonstrated that CAD patients had higher IgG seropositivity as compared to controls (42% vs 23%, P = 0.06). Franceschi et al[78] found that H. pylori Cag-A was significantly associated with acute coronary events (OR = 1.34; 95%CI: 1.15-1.58, P = 0.0003). Niemelä et al[50] showed that the association between CAD and H. pylori infection was not strong. A meta-analysis revealed that there is a little association between H. pylori infection and stroke, but the strength of association was greater for Cag-A positive strains[79]. H. pylori was shown to be associated with premature CAD even in patients without conventional cardiovascular risk factors[80,81]. A number of studies had shown a negative association between H. pylori and CAD which include serological[82,83] and histological studies[84-86]. A negative association is even reported in long term follow-up studies[87]. The Australian Busselton health study comprising of 1612 healthy subjects demonstrated negative association between infection and CAD or stroke[88]. Danesh et al[89] in his meta-analysis of five prospective studies reported no significant association of H. pylori infection with CAD (RR = 1.13). Association of H. pylori infection and outcome of CAD treatment had also been studied. Schiele et al[90] found that H. pylori infection was not a risk factor for restenosis after percutaneous coronary angioplasty. Limnell et al[91] had shown an inverse relationship between H. pylori infection and coronary bypass graft occlusion. Results from Caerphilly heart disease study suggested that Cag-A seropositivity had no relations with CAD or CAD related mortality[92].

H. pylori has been associated with cardiac syndrome X, i.e., angina pectoris with normal epicardial coronaries[28-30]. The proposed mechanism is chronic endothelial dysfunction. Eskandrian et al[28] reported a higher prevalence of H. pylori positivity in syndrome X patients compared to controls (95% vs 47.5%). Patients with syndrome X were found to be more commonly associated with H. pylori Cag-A positivity and elevated IL-1 and TNF-α[93]. Lanza et al[94] has also described association of inflammation, infectious burden and vascular dysfunction. Assadi et al[30] reported 15% of patients with syndrome X had urea breath test (UBT) positivity for H. pylori while none of the patients with chronic stable angina or controls had UBT positivity.

H. pylori and acute myocardial infarction

H. pylori induced inflammatory reaction is possibly responsible for plaque instability and platelet aggregation in acute coronary syndrome patients. Danesh et al[95] demonstrated a higher prevalence of H. pylori infection (42% vs 24%, OR = 1.75) in young acute myocardial infarction (AMI) survivors. Alkout et al[96] showed a higher titre of H. pylori IgG titre in patients who died of AMI (151 ng/mL vs 88 ng/mL, p= 0.034). Kahan et al[97] reported a higher prevalence of H. pylori seropositivity in recent myocardial infarction patients as compared to controls (68% vs 53%, OR = 1.36). This remained significant even after adjusting for other CAD risk factors like age, sex, smoking and hypertension. Kinjo et al[98] suggested that H. pylori infection was significantly associated with AMI in younger patients (age < 55 years, OR = 2.7) but not in those with age of > 55 years. Frazer et al showed a higher prevalence of H. pylori infection in AMI patients compared to control (41.6% vs 34.5%; P = 0.038)[99].

Similar to CAD, negative associations is also been reported between H. pylori and myocardial infarction. Zhu et al[100] hypothesised that H. pylori infection could not lead to CAD or myocardial infarction. Murray et al[101] had shown a negative association between H. pylori and risk for myocardial infarction. Pellicano et al[102] reported a negative association between cytotoxic H. pylori strains and myocardial infarction, with insignificant anti-Cag-A antibody seropositivtiy between cases and controls (33.8% vs 26.8%).

H. pylori Cag-A positivity - Is the risk greater?

Cag-A positivity has raised a curiosity in the infectious theory of atherosclerosis. Several studies had shown a significant relationship between Cag-A strain and CAD or stroke. Carriers of Cag-A positive strains had a higher risk for stroke (OR = 2.99) and carotid plaque instability (OR = 8.42)[103]. De Bastiani et al[104] showed increased prevalence of Cag-A seropositivity and ischemic stroke. Rasmi et al[93] reported a positive relation between Cag-A seropositivity and cardiac syndrome-X. Huang et al[105] revealed that Cag-A positive strains enhanced atherosclerosis in CAD patients by modifying oxidised LDL levels and high sensitive C-reactive protein (hsCRP) levels. Kowalski[36] showed that Cag-A positivity was significantly associated with greater coronary artery lumen loss and restenosis after percutaneous coronary artery stenting. He also demonstrated that H. pylori eradication significantly attenuate reduction in coronary artery lumen after coronary artery stenting[36]. But various authors had denied the excess risk of Cag-A positive strains with atherosclerosis. Koenig et al[106] demonstrated a similar prevalence of Cag-A seropositivity in CAD patients and healthy subjects. Whincup et al[107] in his prospective study comprising of 505 patients and 1025 healthy subjects had clearly shown that there was no significant association of seropositivity with CAD. Murray et al[101] reported negative association between the virulent H. pylori Cag-A strains and acute myocardial infarction.

H. pylori and stroke

By catalysing atherosclerotic pathways, H. pylori infection may be a risk factor for ischemic stroke. Single infectious agent is weakly linked to stroke but cumulative chronic infectious exposures, or “infectious burden”, have been associated with the risk of stroke. The adjusted hazard ratio demonstrating the risk of association between H. pylori and stroke was 1.13, whereas that of infectious burden and stroke was 1.39[108]. The possible mechanisms include macrophage activated plaque destabilization, increased expression of various adhesion molecules and inflammatory cytokines, localized hypercoagulability, altered gene expression, and a molecular mimicry. Markus et al[109] found a higher prevalence of H. pylori seropositivity in stroke cases compared to controls. There was an association between H. pylori infection and large vessel disease and lacunar stroke irrespective of other confounding factors. Another study by Grau et al[110] demonstrated an association between H. pylori seropositivity and ischemic stroke. Elkind et al[111] suggested that that chronic infectious burden results in increase carotid plaque thickness and stroke. A retrospective study reported higher incidence of ischemic stroke in patients with H. pylori infection than in non-infected group (14.8 vs 8.45 per 1000 person years)[112]. Diomedi et al[113] showed that Cag-A positive H. pylori infection was associated with poorer short term clinical outcomes and greater carotid intima media thickness in stroke patients. Increased risk of stroke in Cag-A positive H. pylori patients may be due to enhanced plaque vulnerability[103,114]. In one of the studies, the positive correlation between H. pylori and stroke was confounded by socioeconomic class[115]. A study on chronic bacterial infection and stroke demonstrated that elevated anti- H. pylori antibody was not significantly associated with ischemic stroke[116].

H. pylori and peripheral arterial disease

Studies about association of H. pylori infection with peripheral arterial disease (PAD) are limited. Bloemenkamp et al[117] demonstrated infection as a novel risk factor for PAD in young women. A case control study on infection and PAD in young women suggested that H. pylori infection was positively correlated with PAD only in those with high CRP levels[118]. Sawayama et al[119] reported a significantly higher prevalence of H. pylori infection in PAD cases than in controls (79.7% vs 44.8%; P < 0.01).

CONCLUSION

Overall the association between H. pylori and CAD is not strong and a causal role is yet to be established. Future studies on larger scale may possibly establish a stronger link between the two. If it gets established, there can be drastic reduction in burden of CAD by managing H. pylori infection. Proponents of infectious theory will have a real challenge in the years to come because establishing a definite causal role of H. pylori in CAD will be a nightmare due to the existence of numerous confounding factors. Opponents may continue to criticise the infectious theory of CAD because of lack of strong scientific evidence.

Footnotes

P- Reviewer: Konturek PC, Shimatani T, Slomiany BL, Tosetti C S- Editor: Ma YJ L- Editor: A E- Editor: Lu YJ

References
1.  Frothingham C. The relation between acute infectious diseases and arterial lesions. Arch Intern Med. 1911;8:153.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 34]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
2.  Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with a herpesvirus. Am J Pathol. 1979;96:673-706.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Fabricant CG, Fabricant J, Minick CR, Litrenta MM. Herpesvirus-induced atherosclerosis in chickens. Fed Proc. 1983;42:2476-2479.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Benagiano M, Azzurri A, Ciervo A, Amedei A, Tamburini C, Ferrari M, Telford JL, Baldari CT, Romagnani S, Cassone A. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci USA. 2003;100:6658-6663.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 120]  [Cited by in F6Publishing: 121]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
5.  Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297-329.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 713]  [Cited by in F6Publishing: 744]  [Article Influence: 43.8]  [Reference Citation Analysis (0)]
6.  Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34:2518-2532.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 331]  [Cited by in F6Publishing: 343]  [Article Influence: 16.3]  [Reference Citation Analysis (0)]
7.  Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke. 2001;32:385-391.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 105]  [Cited by in F6Publishing: 109]  [Article Influence: 4.7]  [Reference Citation Analysis (0)]
8.  Farsak B, Yildirir A, Akyön Y, Pinar A, Oç M, Böke E, Kes S, Tokgözoğlu L. Detection of Chlamydia pneumoniae and Helicobacter pylori DNA in human atherosclerotic plaques by PCR. J Clin Microbiol. 2000;38:4408-4411.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Adiloglu AK, Ocal A, Can R, Duver H, Yavuz T, Aridogan BC. Detection of Helicobacter pylori and Chlamydia pneumoniae DNA in human coronary arteries and evaluation of the results with serologic evidence of inflammation. Saudi Med J. 2005;26:1068-1074.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Kaplan M, Yavuz SS, Cinar B, Koksal V, Kut MS, Yapici F, Gercekoglu H, Demirtas MM. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis. 2006;10:116-123.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 49]  [Cited by in F6Publishing: 58]  [Article Influence: 3.1]  [Reference Citation Analysis (0)]
11.  Hoffmeister A, Rothenbacher D, Bode G, Persson K, März W, Nauck MA, Brenner H, Hombach V, Koenig W. Current infection with Helicobacter pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus, is associated with an atherogenic, modified lipid profile. Arterioscler Thromb Vasc Biol. 2001;21:427-432.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 82]  [Cited by in F6Publishing: 89]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
12.  Epstein SE, Zhou YF, Zhu J. Infection and atherosclerosis: emerging mechanistic paradigms. Circulation. 1999;100:e20-e28.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 295]  [Cited by in F6Publishing: 298]  [Article Influence: 11.9]  [Reference Citation Analysis (0)]
13.  Epstein SE, Zhu J, Burnett MS, Zhou YF, Vercellotti G, Hajjar D. Infection and atherosclerosis: potential roles of pathogen burden and molecular mimicry. Arterioscler Thromb Vasc Biol. 2000;20:1417-1420.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 128]  [Cited by in F6Publishing: 138]  [Article Influence: 5.8]  [Reference Citation Analysis (0)]
14.  Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, Schlumberger W, Meyer J. Impact of infectious burden on extent and long-term prognosis of atherosclerosis. Circulation. 2002;105:15-21.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 205]  [Cited by in F6Publishing: 204]  [Article Influence: 9.3]  [Reference Citation Analysis (0)]
15.  Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Victor A, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of infectious burden on progression of carotid atherosclerosis. Stroke. 2002;33:2581-2586.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 124]  [Cited by in F6Publishing: 123]  [Article Influence: 5.6]  [Reference Citation Analysis (0)]
16.  Blankenberg S, Rupprecht HJ, Bickel C, Espinola-Klein C, Rippin G, Hafner G, Ossendorf M, Steinhagen K, Meyer J. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation. 2001;103:2915-2921.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 78]  [Cited by in F6Publishing: 84]  [Article Influence: 3.7]  [Reference Citation Analysis (0)]
17.  Rupprecht HJ, Blankenberg S, Bickel C, Rippin G, Hafner G, Prellwitz W, Schlumberger W, Meyer J. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation. 2001;104:25-31.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 158]  [Cited by in F6Publishing: 171]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
18.  Saikku P. Role of Infection in the Pathogenesis of Coronary Artery Disease. J Interv Cardiol. 1998;11:525-528.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 2]  [Article Influence: 0.1]  [Reference Citation Analysis (0)]
19.  Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, Mänttäri M, Frick MH, Huttunen JK. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med. 1992;116:273-278.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 538]  [Cited by in F6Publishing: 560]  [Article Influence: 17.5]  [Reference Citation Analysis (0)]
20.  Körner I, Blatz R, Wittig I, Pfeiffer D, Rühlmann C. Serological evidence of Chlamydia pneumoniae lipopolysaccharide antibodies in atherosclerosis of various vascular regions. Vasa. 1999;28:259-263.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 15]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
21.  Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation. 1997;96:2144-2148.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 208]  [Cited by in F6Publishing: 219]  [Article Influence: 8.1]  [Reference Citation Analysis (0)]
22.  Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P. Association of Helicobacter pylori infection with elevated serum lipids. Atherosclerosis. 1999;142:207-210.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 112]  [Cited by in F6Publishing: 114]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
23.  Kowalski M, Rees W, Konturek PC, Grove R, Scheffold T, Meixner H, Brunec M, Franz N, Konturek JW, Pieniazek P. Detection of Helicobacter pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina. Dig Liver Dis. 2002;34:398-402.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 45]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
24.  Tousoulis D, Davies GJ, Asimakopoulos G, Homaei H, Zouridakis E, Ahmed N, Kaski JC. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol. 2001;24:301-304.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 51]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
25.  Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y, Yoshizumi M, Kambe M. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol. 2005;45:1219-1222.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 98]  [Cited by in F6Publishing: 112]  [Article Influence: 5.9]  [Reference Citation Analysis (0)]
26.  Coskun S, Kasirga E, Yilmaz O, Bayindir P, Akil I, Yuksel H, Polat M, Sanlidag T. Is Helicobacter pylori related to endothelial dysfunction during childhood? Pediatr Int. 2008;50:150-153.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 14]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
27.  Evrengul H, Tanriverdi H, Kuru O, Enli Y, Yuksel D, Kilic A, Kaftan A, Kirac S, Kilic M. Elevated homocysteine levels in patients with slow coronary flow: relationship with Helicobacter pylori infection. Helicobacter. 2007;12:298-305.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 24]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
28.  Eskandarian R, Malek M, Mousavi SH, Babaei M. Association of Helicobacter pylori infection with cardiac syndrome X. Singapore Med J. 2006;47:704-706.  [PubMed]  [DOI]  [Cited in This Article: ]
29.  Nocente R, Gentiloni N, Cremonini F, Giorgi A, Serricchio M, Santoliquido A, Gasbarrini G, Gasbarrini A. Resolution of syndrome X after eradication of virulent CagA-positive Helicobacter pylori. South Med J. 2000;93:1022-1023.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 2]  [Article Influence: 0.1]  [Reference Citation Analysis (0)]
30.  Assadi M, Saghari M, Ebrahimi A, Reza Pourbehi M, Eftekhari M, Nabipour I, Abbaszadeh M, Nazarahari M, Nasiri M, Assadi S. The relation between Helicobacter pylori infection and cardiac syndrome X: a preliminary study. Int J Cardiol. 2009;134:e124-e125.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 8]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
31.  Gasbarrini A, Massari I, Serricchio M, Tondi P, De Luca A, Franceschi F, Ojetti V, Dal Lago A, Flore R, Santoliquido A. Helicobacter pylori eradication ameliorates primary Raynaud’s phenomenon. Dig Dis Sci. 1998;43:1641-1645.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 1]  [Reference Citation Analysis (0)]
32.  Gasbarrini A, Serricchio M, Tondi P, Gasbarrini G, Pola P. Association of Helicobacter pylori infection with primary Raynaud phenomenon. Lancet. 1996;348:966-967.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 25]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
33.  Russo F, Jirillo E, Clemente C, Messa C, Chiloiro M, Riezzo G, Amati L, Caradonna L, Di Leo A. Circulating cytokines and gastrin levels in asymptomatic subjects infected by Helicobacter pylori (H. pylori). Immunopharmacol Immunotoxicol. 2001;23:13-24.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 41]  [Cited by in F6Publishing: 51]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
34.  Consolazio A, Borgia MC, Ferro D, Iacopini F, Paoluzi OA, Crispino P, Nardi F, Rivera M, Paoluzi P. Increased thrombin generation and circulating levels of tumour necrosis factor-alpha in patients with chronic Helicobacter pylori-positive gastritis. Aliment Pharmacol Ther. 2004;20:289-294.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 20]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
35.  Maciorkowska E, Kaczmarski M, Panasiuk A, Kondej-Muszynska K, Kemonai A. Soluble adhesion molecules ICAM-1, VCAM-1, P-selectin in children with Helicobacter pylori infection. World J Gastroenterol. 2005;11:6745-6750.  [PubMed]  [DOI]  [Cited in This Article: ]
36.  Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol. 2001;52:3-31.  [PubMed]  [DOI]  [Cited in This Article: ]
37.  Brenner H, Berg G, Fröhlich M, Boeing H, Koenig W. Chronic infection with Helicobacter pylori does not provoke major systemic inflammation in healthy adults: results from a large population-based study. Atherosclerosis. 1999;147:399-403.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 24]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
38.  Slomiany BL, Slomiany A. Involvement of p38 MAPK-dependent activator protein (AP-1) activation in modulation of gastric mucosal inflammatory responses to Helicobacter pylori by ghrelin. Inflammopharmacology. 2013;21:67-78.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 27]  [Cited by in F6Publishing: 33]  [Article Influence: 2.8]  [Reference Citation Analysis (0)]
39.  Slomiany BL, Slomiany A. Induction in gastric mucosal prostaglandin and nitric oxide by Helicobacter pylori is dependent on MAPK/ERK-mediated activation of IKK-β and cPLA2: modulatory effect of ghrelin. Inflammopharmacology. 2013;21:241-251.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 32]  [Cited by in F6Publishing: 37]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
40.  Slomiany BL, Slomiany A. Modulation of gastric mucosal inflammatory responses to Helicobacter pylori by ghrelin: Role of cNOS-dependent IKK-β S-nitrosylation in the regulation of COX-2 activation. Am J Mol Biol. 2012;2:113.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 6]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
41.  Slomiany BL, Slomiany A. Role of epidermal growth factor receptor transactivation in the amplification of Helicobacter pylori-elicited induction in gastric mucosal expression of cyclooxygenase-2 and inducible nitric oxide synthase. OA Inflamm. 2013;1:1.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 6]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
42.  Sipponen P, Laxén F, Huotari K, Härkönen M. Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and Helicobacter pylori infection. Scand J Gastroenterol. 2003;38:1209-1216.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 59]  [Cited by in F6Publishing: 64]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]
43.  Tamura A, Fujioka T, Nasu M. Relation of Helicobacter pylori infection to plasma vitamin B12, folic acid, and homocysteine levels in patients who underwent diagnostic coronary arteriography. Am J Gastroenterol. 2002;97:861-866.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 52]  [Cited by in F6Publishing: 53]  [Article Influence: 2.4]  [Reference Citation Analysis (0)]
44.  Santarelli L, Gabrielli M, Cremonini F, Santoliquido A, Candelli M, Nista EC, Pola P, Gasbarrini G, Gasbarrini A. Atrophic gastritis as a cause of hyperhomocysteinaemia. Aliment Pharmacol Ther. 2004;19:107-111.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 29]  [Cited by in F6Publishing: 34]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
45.  Kutluana U, Simsek I, Akarsu M, Kupelioglu A, Karasu S, Altekin E. Is there a possible relation between atrophic gastritis and premature atherosclerosis? Helicobacter. 2005;10:623-629.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 5]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
46.  Senmaru T, Fukui M, Tanaka M, Kuroda M, Yamazaki M, Oda Y, Naito Y, Hasegawa G, Toda H, Yoshikawa T. Atrophic gastritis is associated with coronary artery disease. J Clin Biochem Nutr. 2012;51:39-41.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 9]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
47.  Torisu T, Takata Y, Ansai T, Matsumoto T, Sonoki K, Soh I, Awano S, Yoshida A, Hamasaki T, Kagiyama S. Possible association of atrophic gastritis and arterial stiffness in healthy middle-aged Japanese. J Atheroscler Thromb. 2009;16:691-697.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 13]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
48.  Bloemenkamp DG, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, Algra A, Visseren FL, van der Graaf Y. The relation between Helicobacter pylori and atherosclerosis cannot be explained by a high homocysteine concentration. Eur J Clin Invest. 2002;32:549-555.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 15]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
49.  Murray LJ, Bamford KB, O’Reilly DP, McCrum EE, Evans AE. Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. Br Heart J. 1995;74:497-501.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 89]  [Cited by in F6Publishing: 103]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
50.  Niemelä S, Karttunen T, Korhonen T, Läärä E, Karttunen R, Ikäheimo M, Kesäniemi YA. Could Helicobacter pylori infection increase the risk of coronary heart disease by modifying serum lipid concentrations? Heart. 1996;75:573-575.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 124]  [Cited by in F6Publishing: 133]  [Article Influence: 4.8]  [Reference Citation Analysis (0)]
51.  de Luis DA, Lahera M, Cantón R, Boixeda D, San Román AL, Aller R, de La Calle H. Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. Diabetes Care. 1998;21:1129-1132.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 42]  [Cited by in F6Publishing: 43]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
52.  de Luis DA, Garcia Avello A, Lasuncion MA, Aller R, Martin de Argila C, Boixeda de Miquel D, de la Calle H. Improvement in lipid and haemostasis patterns after Helicobacter pylori infection eradication in type 1 diabetic patients. Clin Nutr. 1999;18:227-231.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 21]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
53.  Majka J, Róg T, Konturek PC, Konturek SJ, Bielański W, Kowalsky M, Szczudlik A. Influence of chronic Helicobacter pylori infection on ischemic cerebral stroke risk factors. Med Sci Monit. 2002;8:CR675-CR684.  [PubMed]  [DOI]  [Cited in This Article: ]
54.  Kanbay M, Gür G, Yücel M, Yilmaz U, Boyacioğlu S. Does eradication of Helicobacter pylori infection help normalize serum lipid and CRP levels? Dig Dis Sci. 2005;50:1228-1231.  [PubMed]  [DOI]  [Cited in This Article: ]
55.  Scharnagl H, Kist M, Grawitz AB, Koenig W, Wieland H, März W. Effect of Helicobacter pylori eradication on high-density lipoprotein cholesterol. Am J Cardiol. 2004;93:219-220.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 42]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
56.  Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ. 1995;311:711-714.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 367]  [Cited by in F6Publishing: 385]  [Article Influence: 13.3]  [Reference Citation Analysis (0)]
57.  Rathbone B, Martin D, Stephens J, Thompson JR, Samani NJ. Helicobacter pylori seropositivity in subjects with acute myocardial infarction. Heart. 1996;76:308-311.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 45]  [Cited by in F6Publishing: 54]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
58.  Wald NJ, Law MR, Morris JK, Bagnall AM. Helicobacter pylori infection and mortality from ischaemic heart disease: negative result from a large, prospective study. BMJ. 1997;315:1199-1201.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 98]  [Cited by in F6Publishing: 104]  [Article Influence: 3.9]  [Reference Citation Analysis (0)]
59.  Danesh J, Peto R. Risk factors for coronary heart disease and infection with Helicobacter pylori: meta-analysis of 18 studies. BMJ. 1998;316:1130-1132.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 168]  [Cited by in F6Publishing: 182]  [Article Influence: 7.0]  [Reference Citation Analysis (0)]
60.  Gillum RF. Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. J Natl Med Assoc. 2004;96:1470-1476.  [PubMed]  [DOI]  [Cited in This Article: ]
61.  Yoshikawa H, Aida K, Mori A, Muto S, Fukuda T. Involvement of Helicobacter pylori infection and impaired glucose metabolism in the increase of brachial-ankle pulse wave velocity. Helicobacter. 2007;12:559-566.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 18]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
62.  Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G, Gun BD, Borazan A, Ustundag Y. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci. 2005;50:2090-2093.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 52]  [Cited by in F6Publishing: 56]  [Article Influence: 2.9]  [Reference Citation Analysis (0)]
63.  Aslan M, Nazligul Y, Horoz M, Bolukbas C, Bolukbas FF, Gur M, Celik H, Erel O. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Atherosclerosis. 2008;196:270-274.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 42]  [Cited by in F6Publishing: 40]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
64.  Gen R, Demir M, Ataseven H. Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation. South Med J. 2010;103:190-196.  [PubMed]  [DOI]  [Cited in This Article: ]
65.  Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Kim BI, Keum DK. Helicobacter pylori eradication has no effect on metabolic and inflammatory parameters. J Natl Med Assoc. 2005;97:508-513.  [PubMed]  [DOI]  [Cited in This Article: ]
66.  Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter. 2011;16:79-88.  [PubMed]  [DOI]  [Cited in This Article: ]
67.  Gunji T, Matsuhashi N, Sato H, Fujibayashi K, Okumura M, Sasabe N, Urabe A. Helicobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population. Am J Gastroenterol. 2008;103:3005-3010.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 99]  [Cited by in F6Publishing: 107]  [Article Influence: 6.7]  [Reference Citation Analysis (0)]
68.  Ando T, Ishikawa T, Takagi T, Imamoto E, Kishimoto E, Okajima A, Uchiyama K, Handa O, Yagi N, Kokura S. Impact of Helicobacter pylori eradication on circulating adiponectin in humans. Helicobacter. 2013;18:158-164.  [PubMed]  [DOI]  [Cited in This Article: ]
69.  Naja F, Nasreddine L, Hwalla N, Moghames P, Shoaib H, Fatfat M, Sibai A, Gali-Muhtasib H. Association of H. pylori infection with insulin resistance and metabolic syndrome among Lebanese adults. Helicobacter. 2012;17:444-451.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 41]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
70.  Migneco A, Ojetti V, Specchia L, Franceschi F, Candelli M, Mettimano M, Montebelli R, Savi L, Gasbarrini G. Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter. 2003;8:585-589.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 42]  [Cited by in F6Publishing: 48]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
71.  Adachi K, Arima N, Takashima T, Miyaoka Y, Yuki M, Ono M, Komazawa Y, Kawamura A, Fujishiro H, Ishihara S. Pulse-wave velocity and cardiovascular risk factors in subjects with Helicobacter pylori infection. J Gastroenterol Hepatol. 2003;18:771-777.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 23]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
72.  Prospective Studies Cooperation. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet. 1995;346:1647-1653.  [PubMed]  [DOI]  [Cited in This Article: ]
73.  Honda C, Adachi K, Arima N, Tanaka S, Yagi J, Morita T, Tanimura T, Furuta K, Kinoshita Y. Helicobacter pylori infection does not accelerate the age-related progression of arteriosclerosis: a 4-year follow-up study. J Gastroenterol Hepatol. 2008;23:e373-e378.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 8]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
74.  Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, Camm AJ, Northfield TC. Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J. 1994;71:437-439.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 409]  [Cited by in F6Publishing: 424]  [Article Influence: 14.1]  [Reference Citation Analysis (0)]
75.  Danesh J. Is there a link between chronic Helicobacter pylori infection and coronary heart disease? Eur J Surg Suppl. 1998;27-31.  [PubMed]  [DOI]  [Cited in This Article: ]
76.  Pellicano R, Mazzarello MG, Morelloni S, Allegri M, Arena V, Ferrari M, Rizzetto M, Ponzetto A. Acute myocardial infarction and Helicobacter pylori seropositivity. Int J Clin Lab Res. 1999;29:141-144.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 18]  [Cited by in F6Publishing: 19]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
77.  Vijayvergiya R, Agarwal N, Bahl A, Grover A, Singh M, Sharma M, Khullar M. Association of Chlamydia pneumoniae and Helicobacter pylori infection with angiographically demonstrated coronary artery disease. Int J Cardiol. 2006;107:428-429.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 9]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
78.  Franceschi F, Niccoli G, Ferrante G, Gasbarrini A, Baldi A, Candelli M, Feroce F, Saulnier N, Conte M, Roccarina D. CagA antigen of Helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases. Atherosclerosis. 2009;202:535-542.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 71]  [Cited by in F6Publishing: 77]  [Article Influence: 5.1]  [Reference Citation Analysis (0)]
79.  Cremonini F, Gabrielli M, Gasbarrini G, Pola P, Gasbarrini A. The relationship between chronic H. pylori infection, CagA seropositivity and stroke: meta-analysis. Atherosclerosis. 2004;173:253-259.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 25]  [Cited by in F6Publishing: 29]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
80.  Goyal P, Kalek SC, Chaudhry R, Chauhan S, Shah N. Association of common chronic infections with coronary artery disease in patients without any conventional risk factors. Indian J Med Res. 2007;125:129-136.  [PubMed]  [DOI]  [Cited in This Article: ]
81.  Vijayvergiya R. Association of infection with coronary artery disease. Indian J Med Res. 2007;125:112-114.  [PubMed]  [DOI]  [Cited in This Article: ]
82.  Al-Nozha MM, Khalil MZ, Al-Mofleh IA, Al-Ghamdi AS. Lack of association of coronary artery disease with H.pylori infection. Saudi Med J. 2003;24:1370-1373.  [PubMed]  [DOI]  [Cited in This Article: ]
83.  Kanbay M, Gür G, Yücel M, Yilmaz U, Muderrisoglu H. Helicobacter pylori seroprevalence in patients with coronary artery disease. Dig Dis Sci. 2005;50:2071-2074.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 8]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
84.  Basili S, Vieri M, Di Lecce VN, Maccioni D, Marmifero M, Paradiso M, Labbadia G, Spada S, Cordova C, Alessandri C. Association between histological diagnosis of Helicobacter pylori and coronary heart disease: results of a retrospective study. Clin Ter. 1998;149:413-417.  [PubMed]  [DOI]  [Cited in This Article: ]
85.  Bielański W. Epidemiological study on Helicobacter pylori infection and extragastroduodenal disorders in Polish population. J Physiol Pharmacol. 1999;50:723-733.  [PubMed]  [DOI]  [Cited in This Article: ]
86.  Quinn MJ, Foley JB, Mulvihill NT, Lee J, Crean PA, Walsh MJ, O’Morain CA. Helicobacter pylori serology in patients with angiographically documented coronary artery disease. Am J Cardiol. 1999;83:1664-1666, A6.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 11]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
87.  Haider AW, Wilson PW, Larson MG, Evans JC, Michelson EL, Wolf PA, O’Donnell CJ, Levy D. The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. J Am Coll Cardiol. 2002;40:1408-1413.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 71]  [Cited by in F6Publishing: 79]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
88.  Coles KA, Knuiman MW, Plant AJ, Riley TV, Smith DW, Divitini ML. A prospective study of infection and cardiovascular diseases: the Busselton Health Study. Eur J Cardiovasc Prev Rehabil. 2003;10:278-282.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 17]  [Cited by in F6Publishing: 23]  [Article Influence: 1.2]  [Reference Citation Analysis (0)]
89.  Danesh J. Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: meta-analyses of prospective studies. Am Heart J. 1999;138:S434-S437.  [PubMed]  [DOI]  [Cited in This Article: ]
90.  Schiele F, Batur MK, Seronde MF, Meneveau N, Sewoke P, Bassignot A, Couetdic G, Caulfield F, Bassand JP. Cytomegalovirus, Chlamydia pneumoniae, and Helicobacter pylori IgG antibodies and restenosis after stent implantation: an angiographic and intravascular ultrasound study. Heart. 2001;85:304-311.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 14]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
91.  Limnell V, Pasternack R, Karjalainen J, Virtanen V, Lehtimäki T, Aittoniemi J. Seropositivity for Helicobacter pylori antibodies is associated with lower occurrence of venous bypass graft occlusion. Scand J Infect Dis. 2004;36:601-603.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 3]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
92.  Stone AF, Risley P, Markus HS, Butland BK, Strachan DP, Elwood PC, Mendall MA. Ischaemic heart disease and Cag A strains of Helicobacter pylori in the Caerphilly heart disease study. Heart. 2001;86:506-509.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 20]  [Cited by in F6Publishing: 22]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
93.  Rasmi Y, Raeisi S, Seyyed Mohammadzad MH. Association of inflammation and cytotoxin-associated gene a positive strains of helicobacter pylori in cardiac syndrome x. Helicobacter. 2012;17:116-120.  [PubMed]  [DOI]  [Cited in This Article: ]
94.  Lanza GA, Sestito A, Cammarota G, Grillo RL, Vecile E, Cianci R, Speziale D, Dobrina A, Maseri A, Crea F. Assessment of systemic inflammation and infective pathogen burden in patients with cardiac syndrome X. Am J Cardiol. 2004;94:40-44.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 52]  [Cited by in F6Publishing: 44]  [Article Influence: 2.2]  [Reference Citation Analysis (0)]
95.  Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. BMJ. 1999;319:1157-1162.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 86]  [Cited by in F6Publishing: 85]  [Article Influence: 3.4]  [Reference Citation Analysis (0)]
96.  Alkout AM, Ramsay EJ, Mackenzie DA, Weir DM, Bentley AJ, Elton RA, Sutherland S, Busuttil A, Blackwell CC. Quantitative assessment of IgG antibodies to Helicobacter pylori and outcome of ischaemic heart disease. FEMS Immunol Med Microbiol. 2000;29:271-274.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 10]  [Article Influence: 0.4]  [Reference Citation Analysis (0)]
97.  Kahan T, Lundman P, Olsson G, Wendt M. Greater than normal prevalence of seropositivity for Helicobacter pylori among patients who have suffered myocardial infarction. Coron Artery Dis. 2000;11:523-526.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 19]  [Cited by in F6Publishing: 21]  [Article Influence: 0.9]  [Reference Citation Analysis (0)]
98.  Kinjo K, Sato H, Sato H, Shiotani I, Kurotobi T, Ohnishi Y, Hishida E, Nakatani D, Mizuno H, Sasaki T. Prevalence of Helicobacter pylori infection and its link to coronary risk factors in Japanese patients with acute myocardial infarction. Circ J. 2002;66:805-810.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 34]  [Cited by in F6Publishing: 39]  [Article Influence: 1.8]  [Reference Citation Analysis (0)]
99.  Fraser AG, Scragg RK, Cox B, Jackson RT. Helicobacter pylori, Chlamydia pneumoniae and myocardial infarction. Intern Med J. 2003;33:267-272.  [PubMed]  [DOI]  [Cited in This Article: ]
100.  Zhu J, Quyyumi AA, Muhlestein JB, Nieto FJ, Horne BD, Zalles-Ganley A, Anderson JL, Epstein SE. Lack of association of Helicobacter pylori infection with coronary artery disease and frequency of acute myocardial infarction or death. Am J Cardiol. 2002;89:155-158.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 31]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
101.  Murray LJ, Bamford KB, Kee F, McMaster D, Cambien F, Dallongeville J, Evans A. Infection with virulent strains of Helicobacter pylori is not associated with ischaemic heart disease: evidence from a population-based case-control study of myocardial infarction. Atherosclerosis. 2000;149:379-385.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 34]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
102.  Pellicano R, Parravicini PP, Bigi R, Gandolfo N, Aruta E, Gai V, Figura N, Angelino P, Rizzetto M, Ponzetto A. Infection by Helicobacter pylori and acute myocardial infarction. Do cytotoxic strains make a difference? New Microbiol. 2002;25:315-321.  [PubMed]  [DOI]  [Cited in This Article: ]
103.  Gabrielli M, Santoliquido A, Cremonini F, Cicconi V, Candelli M, Serricchio M, Tondi P, Pola R, Gasbarrini G, Pola P. CagA-positive cytotoxic H. pylori strains as a link between plaque instability and atherosclerotic stroke. Eur Heart J. 2004;25:64-68.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 41]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
104.  De Bastiani R, Gabrielli M, Ubaldi E, Benedetto E, Sanna G, Cottone C, Candelli M, Zocco MA, Saulnier N, Santoliquido A. High prevalence of Cag-A positive H. pylori strains in ischemic stroke: a primary care multicenter study. Helicobacter. 2008;13:274-277.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 26]  [Article Influence: 1.6]  [Reference Citation Analysis (0)]
105.  Huang B, Chen Y, Xie Q, Lin G, Wu Y, Feng Y, Li J, Zhuo Y, Zhang P. CagA-positive Helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease. Dig Dis Sci. 2011;56:109-114.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 39]  [Cited by in F6Publishing: 41]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
106.  Koenig W, Rothenbacher D, Hoffmeister A, Miller M, Bode G, Adler G, Hombach V, März W, Pepys MB, Brenner H. Infection with Helicobacter pylori is not a major independent risk factor for stable coronary heart disease: lack of a role of cytotoxin-associated protein A-positive strains and absence of a systemic inflammatory response. Circulation. 1999;100:2326-2331.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 46]  [Cited by in F6Publishing: 48]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
107.  Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Hawkey C, Atherton J. Prospective study of potentially virulent strains of Helicobacter pylori and coronary heart disease in middle-aged men. Circulation. 2000;101:1647-1652.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 77]  [Article Influence: 3.2]  [Reference Citation Analysis (0)]
108.  Elkind MS. Inflammatory mechanisms of stroke. Stroke. 2010;41:S3-S8.  [PubMed]  [DOI]  [Cited in This Article: ]
109.  Markus HS, Mendall MA. Helicobacter pylori infection: a risk factor for ischaemic cerebrovascular disease and carotid atheroma. J Neurol Neurosurg Psychiatry. 1998;64:104-107.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 89]  [Cited by in F6Publishing: 93]  [Article Influence: 3.6]  [Reference Citation Analysis (0)]
110.  Grau AJ, Buggle F, Lichy C, Brandt T, Becher H, Rudi J. Helicobacter pylori infection as an independent risk factor for cerebral ischemia of atherothrombotic origin. J Neurol Sci. 2001;186:1-5.  [PubMed]  [DOI]  [Cited in This Article: ]
111.  Elkind MS, Luna JM, Moon YP, Boden-Albala B, Liu KM, Spitalnik S, Rundek T, Sacco RL, Paik MC. Infectious burden and carotid plaque thickness: the northern Manhattan study. Stroke. 2010;41:e117-e122.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 28]  [Reference Citation Analysis (0)]
112.  Huang WS, Tseng CH, Lin CL, Tsai CH, Kao CH. Helicobacter pylori infection increases subsequent ischemic stroke risk: a nationwide population-based retrospective cohort study. QJM. 2014;107:969-975.  [PubMed]  [DOI]  [Cited in This Article: ]
113.  Diomedi M, Pietroiusti A, Silvestrini M, Rizzato B, Cupini LM, Ferrante F, Magrini A, Bergamaschi A, Galante A, Bernardi G. CagA-positive Helicobacter pylori strains may influence the natural history of atherosclerotic stroke. Neurology. 2004;63:800-804.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 39]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
114.  Pietroiusti A, Diomedi M, Silvestrini M, Cupini LM, Luzzi I, Gomez-Miguel MJ, Bergamaschi A, Magrini A, Carrabs T, Vellini M. Cytotoxin-associated gene-A--positive Helicobacter pylori strains are associated with atherosclerotic stroke. Circulation. 2002;106:580-584.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 83]  [Cited by in F6Publishing: 90]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
115.  Whincup PH, Mendall MA, Perry IJ, Strachan DP, Walker M. Prospective relations between Helicobacter pylori infection, coronary heart disease, and stroke in middle aged men. Heart. 1996;75:568-572.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 114]  [Cited by in F6Publishing: 138]  [Article Influence: 4.9]  [Reference Citation Analysis (0)]
116.  Heuschmann PU, Neureiter D, Gesslein M, Craiovan B, Maass M, Faller G, Beck G, Neundoerfer B, Kolominsky-Rabas PL. Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: Results from a population-based case-control study. Stroke. 2001;32:2253-2258.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 81]  [Cited by in F6Publishing: 94]  [Article Influence: 4.1]  [Reference Citation Analysis (0)]
117.  Bloemenkamp DG, van den Bosch MA, Mali WP, Tanis BC, Rosendaal FR, Kemmeren JM, Algra A, Visseren FL, van der Graaf Y. Novel risk factors for peripheral arterial disease in young women. Am J Med. 2002;113:462-467.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 40]  [Cited by in F6Publishing: 33]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
118.  Bloemenkamp DG, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, Algra A, Ossewaarde JM, Visseren FL, van Loon AM. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. Atherosclerosis. 2002;163:149-156.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 30]  [Cited by in F6Publishing: 32]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
119.  Sawayama Y, Hamada M, Otaguro S, Maeda S, Ohnishi H, Fujimoto Y, Taira Y, Hayashi J. Chronic Helicobacter pylori infection is associated with peripheral arterial disease. J Infect Chemother. 2008;14:250-254.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 17]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]